Critical Market Drivers Shaping the Outlook for Rare Biomarkers Specimen Collection And Stabilization Market from 2025-2034: Increasing Prevalence Of Cancer Is Driving The Growth Of The Rare Bio Markers Specimen Collection And Stabilization
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Estimated Market Size of the Rare Biomarkers Specimen Collection And Stabilization Market In 2029?
The market size for rare biomarkers specimen collection and stabilization has experienced significant growth in the past few years. Expected to expand from $32.01 billion in 2024 to $35.29 billion in 2025, the market exhibits a compound annual growth rate (CAGR) of 10.3%. Several factors contributed to this growth during the historical period, including the human genome project, a surge in cancer research, investments in pharmaceutical R&D, the expansion of genomics and proteomics, and advancements in data management and bioinformatics.
The market for the collection and stabilization of rare biomarkers specimens is anticipated to experience robust growth in the upcoming years, with its value expected to reach $51.22 billion in 2029, reflecting a compound annual growth rate (CAGR) of 9.8%. The expansion during the forecast period can be credited to various factors such as the broadening applications of liquid biopsy, growing consumer consciousness and demand, increasing preference for non-invasive techniques, and discovery of biomarkers in rare diseases. Notable market trends during this period include the improvement of preservation technology, expansion of genomic and proteomic research, the rise of point-of-care testing, progressive regulatory and standardization measures, enhanced data analytics capabilities, and the incorporation of artificial intelligence.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp
What Are the Core Growth Drivers Propelling the Rare Biomarkers Specimen Collection And Stabilization Market Forward?
The rising incidence of cancer is anticipated to fuel the expansion of the rare biomarker specimen collection and stabilization market in the future. Cancer, characterized by the uncontrolled growth and spread of abnormal cells, is a series of diseases. Factors such as environmental pollutants and lifestyle choices, including smoking and poor dietary habits, intensify genetic vulnerabilities, leading to an increase in the prevalence of cancer. The application of rare biomarker specimen collection and stabilization techniques in studies related to cancer prevalence enables more precise identification and tracking of distinct types of cancer, thus improving the diagnostic and treatment strategies. For example, a report by the European Commission, a governing body situated in Europe, stated in October 2023 that new cancer cases reached 2.74 million in 2022, indicating a 2.3% surge since 2020. Therefore, the escalating incidence of cancer is driving the expansion of the rare biomarker specimen collection and stabilization market.
What Segment Types Define the Rare Biomarkers Specimen Collection And Stabilization Market Structure?
The rare biomarkers specimen collection and stabilizationmarket covered in this report is segmented –
1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA); Circulating Tumor Cells (CTCs); Exosomes or Extracellular Vesicles
2) By Specimen: Serum Or Plasma; Other Specimens
3) By Application: Non-Invasive Prenatal Testing (NIPT); Oncology; Transcriptomics; Pharmacogenomics; Transplant Rejection; Population Screening; Cardiovascular Diseases; Other Applications
4) By End-User: Hospitals; Perinatal Clinics; Public Health Labs; Private Or Commercial Labs; Physician Labs; Research Institutes; Other End-Users
Subsegments:
1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA; Serum CCFDNA
2) By Circulating Tumor Cells (CTCs): CTCs In Blood; CTCs In Bone Marrow
3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma; Exosomes From Serum
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=15913&type=smp
Which Geographic Areas Hold the Strongest Growth Potential in the Rare Biomarkers Specimen Collection And Stabilization Market?
North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Which Emerging Trends that Are Influencing theRare Biomarkers Specimen Collection And Stabilization Industry Evolution?
In the rare biomarker specimen collection and stabilization marketplace, leading corporations are concentrating on crafting inventive solutions such as a pre-analytical platform. This new development can automate both the plasma and cell sample preparation processes for multiomic liquid biopsies at the time of blood collection. This platform is notable for its ability to work independently, negating the need for special tubes or highly trained staff while maintaining the sample’s integrity. Tethis S.p.A., a biotech firm based in Italy, introduced See.d in May 2022, the premier fully automated, standardized pre-analytical platform. It is equipped with exclusive features including accurate sample manipulation, effective plasma separation for cellular portions, and the securing of white blood cells on SmartBioSurface slides. This system also includes an evaluation component for objective assessment of sample stability. The resulting systematic scoring of proteomic and metabolomic data assists in determining the stability of plasma and serum samples.
View the full report here:
What Is the Definition of the Rare Biomarkers Specimen Collection And Stabilization Market?
Rare biomarkers specimen collection and stabilization refers to the process of collecting and preserving biological samples containing rare or low-abundance molecules that serve as indications of specific biological processes, diseases, or situations. These biomarkers could be specific proteins, nucleic acids, metabolites, or other substances. The aim of collecting and preserving rare biomarkers is to enable accurate and reliable measurement and analysis of these molecules for diagnostic, prognostic, and therapeutic applications.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15913
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
